In vitro investigation of 225Ac-PSMA I&T and its decay products on PSMA expressing cancer cells
Prostate-specific membrane antigen (PSMA)-targeted ligands, labeled with the alpha-emitter 225 Achave shown promise for treatment of177 Lu-PSMA refractory metastatic castration resistant prostate cancer(mCRPC). However the complex decay chain of 225 Ac with several decay products poses additional risks,compared to beta-emitting ligands, such as 177 Lu-PSMA. The emission of the first alpha particle from 221 Ac resultsin dissociation of the decay isotope 221 Fr from the metal chelate, leading to a biodistribution o f221 Fr and itsradioactive decay products that may differ from the biodistribution of the parent compound225 Ac-PSMA I&T.
Aim:We assessed the internalization and externalization kinetics of225 Ac-PSMA I&T and225 Ac decay products in PSMAexpressing cancer cells and compared the results to the kinetics of117 Lu-PSMA I&T.
WURZER A;
SALEH Samaa;
KOSSATZ Susanne;
SEIDL C.;
EIBER Matthias;
HÜRKAMP Kerstin;
LI Wei Bo;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
D'ALESSANDRIA C;
WEBER Wolfgang;
2022-12-19
SOC NUCLEAR MEDICINE INC
JRC128886
0161-5505 (online),
Additional supporting files
| File name | Description | File type | |
|---|
